$CBPO News
Last published 2y ago
- 2y agoAMGNCBPOGFYFDA Approves First Interchangeable Biosimilar for Two Rare DiseasesFDA Press ReleasesToday, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; and the treatment of patie ...
- 3y agoCBPOFDA Approves First Biosimilar to Treat Multiple SclerosisFDA Press ReleasesThe U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). Tyruko, like Tysabri, is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s Disease (CD) with evidenc ...
- 4y agoCBPOChina Biologic Privatization Transaction Led by Centurium Capital Wins AVCJ "Deal of the Year - Large Cap"PR NewswireHONG KONG, Nov. 16, 2021 /PRNewswire/ -- The Centurium Capital-led privatization of leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc. ("China Biologic" or the "Company") was awarded "Deal of the Year – Large Cap" by A
- 5y agoCBPOChina Biologic Announces Completion of Going Private TransactionPR NewswireBEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ:CBPO, ", China Biologic", or the ", Company", ))), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its
- 5y agoCBPOChina Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020PR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 5y agoCBPOChina Biologic Announces Shareholders' Approval of Merger AgreementPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 5y agoCBPOChina Biologic Announces Extraordinary General Meeting of ShareholdersPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 5y agoCBPOChina Biologic Reports Financial Results for the Third Quarter of 2020PR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 5y agoCBPOChina Biologic Enters into Definitive Merger Agreement for Going Private TransactionPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 5y agoCBPOChina Biologic Products to Report Third Quarter 2020 Financial ResultsPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 6y agoCBPOChina Biologic Reports Financial Results for the Second Quarter of 2020PR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 6y agoCBPOChina Biologic Products to Report Second Quarter 2020 Financial ResultsPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 6y agoCBPOChina Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin TransactionPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 6y agoJDNTESDLCBPO+3China Inc. Pulls Out of U.S. Market at Fastest Pace Since 2015BloombergChinese companies are ditching their U.S. listings at the fastest pace since 2015 as they grapple with rising tensions between Beijing and Washington.
- 6y agoCBPOChina Biologic Comments on the Xinjiang Deyuan and Shuanglin TransactionPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 6y agoCBPOChina Biologic Reports Financial Results for the First Quarter of 2020PR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 6y agoCBPOChina Biologic Products to Report First Quarter 2020 Financial ResultsPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 6y agoCBPOInsulin Gains New Pathway to Increased CompetitionFDA Press ReleasesStatement From: Statement Author Leadership Role Principal Deputy Commissioner - Office of the Commissioner Amy Abernethy MD, PhD. Leadership Role Director - Center for Drug Evaluation and Research Janet Woodcock M.D. Today is a historic day and a landmark moment for patients with diabetes and other serious medical conditions, as insulin and certain other biologic drugs transition to a different r ...
- 6y agoCBPOChina Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019PR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 6y agoCBPOChina Biologic, Suitor Are in Advanced Talks on Take-PrivateBloombergA Chinese buyout group is in advanced talks to take New York-listed China Biologic Products Holdings Inc. private, according to people with knowledge of the matter.
- 6y agoCBPOCenturium Capital and Certain Other Investors File a Transaction Statement on Schedule 13E-3 with the U. S. Securities and Exchange CommissionPR NewswireCenturium Capital, a leading private equity firm in China, today announced that several of its affiliate entities, namely Beachhead Holdings Limited...
- 7y agoCBPOChina Biologic Reports Financial Results for the Third Quarter of 2019PR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 7y agoCBPOChina Biologic Bidder Seeks Over $1 Billion in FinancingBloombergA consortium seeking to take China Biologic Products Holdings Inc. private is in talks with banks for more than $1 billion of funding to back its bid, according to people familiar with the matter.
- 7y agoCBPOChina Biologic Products to Report Third Quarter 2019 Financial ResultsPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 7y agoCBPOChina Biologic Special Committee Retains Financial Advisor and Legal CounselPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 7y agoCBPOChina Biologic Forms Special Committee to Review "Going Private" ProposalPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 7y agoCBPOChina Biologic Announces Receipt of Preliminary Non-Binding "Going Private" ProposalPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 7y agoCBPOChina Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoCBPOChina Biologic Reports Financial Results for the Second Quarter of 2019PR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 7y agoCBPOChina Biologic Products to Report Second Quarter 2019 Financial ResultsPR NewswireChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical...
- 7y agoCBPOChina Biologic Products Holdings, Inc. (CBPO) Management on Q1 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoCBPOChina Biologic Products, Inc. (CBPO) CEO Bing Li on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoCBPODavid Gao Issues Statement Following Decision by the Grand Court of the Cayman IslandsBusiness WireBEIJING--(BUSINESS WIRE)--Mr. David (Xiaoying) Gao, a shareholder of China Biologic Products Holdings, Inc. (“China Biologic” or the “Company”) (NASDAQ: CBPO), today issued the following statement on the Grand Court of the Cayman Islands’ recent decision regarding his lawsuit against the Company:
- 8y agoCBPOChina Biologic Products' (CBPO) CEO Bing Li on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoCBPODavid Gao Confirms Lawsuit Against China Biologic Products to Protect Shareholders’ Best InterestsBusiness WireBEIJING--(BUSINESS WIRE)--Mr. David (Xiaoying) Gao, a shareholder of China Biologic Products Holdings, Inc. (“China Biologic” or the “Company”) (NASDAQ: CBPO), today confirmed that he filed a lawsuit against the Company related to its private placement of shares to a select investor group – including a private equity firm formed by Board Chairman David Li.
- 8y agoCBPOLeading Investor Group Issues Statement Following China Biologic’s Dilutive Private Placement of SharesBusiness WireBEIJING--(BUSINESS WIRE)--A consortium composed of Mr. David (Xiaoying) Gao, GL Capital Group, Bank of China Group Investment Limited and CDH Investments (the “Consortium”) today issued the following statement following China Biologic Products Holdings, Inc.’s (“China Biologic” or the “Company”) (NASDAQ: CBPO) decision to conduct a dilutive private placement and reject the Consortium’s non-binding ...
- 8y agoCBPOBJGPLeading Investor Group Proposes to Acquire China Biologic Products for US$118.00 Per Share in CashBusiness WireBEIJING--(BUSINESS WIRE)--A consortium composed of Mr. David (Xiaoying) Gao, GL Capital Group, Bank of China Group Investment Limited and CDH Investments (the “Consortium”) today announced it has made a non-binding proposal to acquire all of the outstanding common shares of China Biologic Products Holdings, Inc. (“China Biologic” or the “Company”) (NASDAQ: CBPO), that are not already held by the C ...
- 8y agoCBPOChina Biologic Products, Inc. (CBPO) Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoCBPOChina Biologic Products' (CBPO) CEO David Gao on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts